Erica L. Mayer
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston
Massachusetts 02215
USA
Name/email consistency: high
- A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Mayer, E.L., Baurain, J.F., Sparano, J., Strauss, L., Campone, M., Fumoleau, P., Rugo, H., Awada, A., Sy, O., Llombart-Cussac, A. Clin. Cancer Res. (2011)